相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project
Lucas Moreno et al.
PEDIATRIC BLOOD & CANCER (2021)
The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project
Veronica Moroz et al.
PEDIATRIC BLOOD & CANCER (2020)
Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future
Wayne H. Liang et al.
JCO CLINICAL CANCER INFORMATICS (2020)
Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma
Derek A. Oldridge et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Telomere Maintenance in Pediatric Cancer
Sandra Ackermann et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The challenge of defining ultra-high-risk neuroblastoma
Daniel A. Morgenstern et al.
PEDIATRIC BLOOD & CANCER (2019)
Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)
Tomoro Hishiki et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients
Pauline Depuydt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study
Daniel A. Morgenstern et al.
PEDIATRIC BLOOD & CANCER (2018)
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients
Pauline Depuydt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
A mechanistic classification of clinical phenotypes in neuroblastoma
Sandra Ackermann et al.
SCIENCE (2018)
Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis
Kumiko Uryu et al.
ONCOTARGET (2017)
Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway
Yuanyuan Li et al.
ONCOTARGET (2017)
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database
Daniel A. Morgenstern et al.
EUROPEAN JOURNAL OF CANCER (2016)
Neuroblastoma
Katherine K. Matthay et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld et al.
NATURE GENETICS (2015)
Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
Andre Oberthuer et al.
CLINICAL CANCER RESEARCH (2015)
Successful treatment of infants with localized neuroblastoma based on their MYCN status
Tomoko Iehara et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
G. Schleiermacher et al.
BRITISH JOURNAL OF CANCER (2012)
Is the prognosis of stage 4s neuroblastoma in patients 12 months of age and older really excellent?
Tomoko Iehara et al.
EUROPEAN JOURNAL OF CANCER (2012)
Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma
Nai-Kong V. Cheung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
G. Schleiermacher et al.
BRITISH JOURNAL OF CANCER (2011)
Global genomic and RNA profiles for novel risk stratification of neuroblastoma
Miki Ohira et al.
CANCER SCIENCE (2010)
Prognostic Impact of Gene Expression-Based Classification for Neuroblastoma
Andre Oberthuer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Accumulation of Segmental Alterations Determines Progression in Neuroblastoma
Gudrun Schleiermacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Medical Progress: Recent Advances in Neuroblastoma.
John M. Maris
NEW ENGLAND JOURNAL OF MEDICINE (2010)
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
P. F. Ambros et al.
BRITISH JOURNAL OF CANCER (2009)
Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma
Isabelle Janoueix-Lerosey et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Tom Monclair et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Susan L. Cohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study
Eiso Hiyama et al.
LANCET (2008)
Oncogenic mutations of ALK kinase in neuroblastoma
Yuyan Chen et al.
NATURE (2008)
Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression
Yael P. Mosse et al.
GENES CHROMOSOMES & CANCER (2007)
Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification
G. Schleiermacher et al.
BRITISH JOURNAL OF CANCER (2007)
MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening
T. Iehara et al.
BRITISH JOURNAL OF CANCER (2006)
Chromosome 1p and 11q deletions and outcome in neuroblastoma
EF Attiyeh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Neuroblastoma: Biological insights into a clinical enigma
GM Brodeur
NATURE REVIEWS CANCER (2003)
Chromosomes that show partial loss or gain in near-diploid tumors coincide with chromosomes that show whole loss or gain in near-triploid tumors: Evidence suggesting the involvement of the same genes in the tumorigenesis of high- and low-risk neuroblastomas
N Tomioka et al.
GENES CHROMOSOMES & CANCER (2003)
Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification
M Kaneko et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2002)
Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group study
JM Maris et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
